Foresight Diagnostics

Allogene Therapeutics Inc. announced that Rocky Mountain Cancer Centers, part of the US Oncology Network and Sarah Cannon Research Institute ; Astera Cancer Care, a multi-specialty community oncology practice and part of the OneOncology network; and Norton Cancer Institute, are open for enrollment in the pivotal Phase 2 ALPHA3 trial.

Allogene Therapeutics Inc. announced the initiation of the pivotal Phase 2 ALPHA3 trial evaluating the use of cemacabtagene ansegedleucel as part of the first line treatment regimen for newly diagnosed LBCL patients who are likely to relapse after standard 1L treatment and need further therapy.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended March 31, 2024.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) today provided a corporate update and reported financial results for the quarter and year ended December 31, 2023.

Allogene Therapeutics Inc. and Foresight Diagnostics announced a strategic partnership to develop a minimal residual disease in-vitro diagnostic to determine eligibility in ALPHA3, the first pivotal trial for first line consolidation treatment of large B-cell lymphoma.

Allogene Therapeutics, Inc. announced its 2024 Platform Vision that redefines the future of CAR T by leveraging the unique attributes of allogeneic CAR T products.

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection testing, announced today that six studies utilizing their patented PhasED-Seq™ technology will be presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023) taking place December 9-12, 2023, in San Diego, California.